• Triple-Negative Breast Cancer — Fifth Annual National General Medical Oncology Summit
    Jun 20 2026

    Featuring perspectives from Dr Adam M Brufsky and Dr Kevin Kalinsky, including the following topics:

    • Introduction (0:00)
    • Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Therapy for Triple-Negative Breast Cancer (TNBC) — Dr Brufsky (5:08)
    • Established Treatment Paradigm for Localized and Metastatic TNBC — Dr Kalinsky (35:20)

    CME information and select publications

    Show More Show Less
    49 mins
  • Desmoid Tumors — Microlearning Activity 4 with Prof Bernd Kasper
    Jun 20 2026

    Featuring an interview with Prof Bernd Kasper, including the following topics:

    • Case: A woman in her early 30s develops a progressing desmoid tumor in her abdomen during pregnancy(0:00)
    • Case: A woman in her late 30s with a painful small desmoid tumor in her rectus abdominus undergoes cryoablation (8:04)
    • Case: A woman in her late teens with recurrent desmoid tumors in her right thigh undergoes multiple resections (13:58)
    • Case: A woman in her mid 70s has a desmoid tumor causing erosion in her scapular region (17:19)

    CME information and select publications

    Show More Show Less
    24 mins
  • Ovarian Cancer — Fifth Annual National General Medical Oncology Summit
    Jun 19 2026

    Featuring perspectives from Dr Deborah K Armstrong and Dr David M O'Malley, including the following topics:

    • Introduction (0:00)
    • PARP Inhibitors and Strategies Targeting Folate Receptor Alpha in Advanced Ovarian Cancer — Dr Armstrong (4:37)
    • Other Novel Agents and Strategies for the Treatment of Advanced Ovarian Cancer — Dr O'Malley (35:18)

    CME information and select publications

    Show More Show Less
    54 mins
  • Gastroesophageal Cancers — Fifth Annual National General Medical Oncology Summit
    Jun 19 2026

    Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, including the following topics:

    • Introduction (0:00)
    • Role of Anti-PD-1/PD-L1- and CLDN18.2-Directed Antibodies in the Management of Gastroesophageal Cancers — Dr Klempner (5:52)
    • Management of HER2-Positive Gastroesophageal Cancers — Dr Janjigian (28:20)

    CME information and select publications

    Show More Show Less
    51 mins
  • Multiple Myeloma — Fifth Annual National General Medical Oncology Summit
    Jun 18 2026

    Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:

    • Introduction (0:00)
    • Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30)
    • Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33)

    CME information and select publications

    Show More Show Less
    47 mins
  • First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck (Companion Faculty Lecture)
    Jun 18 2026

    Featuring a slide presentation and related discussion from Prof Martin Reck, including the following topics:

    • Overview of small cell lung cancer (SCLC) (0:00)
    • First-line chemoimmunotherapy for extensive-stage SCLC (ES-SCLC) (3:50)
    • Lurbinectedin as first-line maintenance therapy for ES-SCLC (12:36)
    • Case: A man in his early 60s with ES-SCLC receives first-line atezolizumab/carboplatin/etoposide followed by maintenance lurbinectedin/atezolizumab (18:46)
    • Case: A woman in her mid 70s with ES-SCLC experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (21:21)

    CME information and select publications

    Show More Show Less
    25 mins
  • First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck
    Jun 18 2026

    Featuring an interview with Prof Martin Reck, including the following topics:

    • Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00)
    • Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25)
    • Considerations with maintenance therapy for ES-SCLC (9:31)
    • Considerations with immunotherapy for ES-SCLC (13:12)
    • Curability of SCLC with systemic therapy (15:17)
    • Data with chemoimmunotherapy for patients with poor performance status (25:55)
    • Future developments in therapy for SCLC (30:11)
    • Rapid fire: Small Cell 101 (35:45)

    CME information and select publications

    Show More Show Less
    41 mins
  • Urothelial Bladder Cancer — Fifth Annual National General Medical Oncology Summit
    Jun 18 2026

    Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics:

    • Introduction (0:00)
    • Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)
    • Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41)

    CME information and select publications

    Show More Show Less
    49 mins